M&A

Stryker's 27-year veteran Spencer Stiles will become CEO on 1 January 2027, as Kevin Lobo transitions to Executive Chair after tripling annual revenues.

Nasdaq-listed Cuprina is buying East Coast Podiatry and Orchard Clinic to integrate clinical delivery with its wound-care and collagen technologies.

The Nasdaq-listed ophthalmic biotech has acquired its existing IOL manufacturer from Santen, securing Phase 3 supply and a route to premium lens options.

London PE firm Samfara has completed its first acquisition, buying Danish cGMP manufacturer Chr. Olesen Synthesis, which specialises in buprenorphine and lisdexamfetamine

Wandercraft's all-cash deal for Ekso Bionics creates a combined portfolio of four medical exoskeletons across rehabilitation and personal mobility markets.

Webster Equity Partners will acquire the CDMO for $6.28 per share in cash, plus CVRs worth up to $9.67 per share if performance

Telix Pharmaceuticals will merge with ITM Isotope Technologies Munich in a deal worth up to $2.35bn including milestones, creating a vertically integrated

Lisata is pivoting to cardioendocrine disease after acquiring Marea Therapeutics in a stock deal backed by a $225m oversubscribed private placement.

Veracyte is adding the UroAmp urinary tumour DNA platform to its bladder cancer portfolio, with commercialisation targeted for late 2028.

Axogen is selling 4.91 million shares at $42.50 each, with proceeds earmarked to finance its pending acquisition of BioCircuit Technologies.

Red White & Bloom has entered Germany and the UK via a deal giving it majority control of an integrated medical cannabis platform dispensing over 12

CooperCompanies concluded its nine-month strategic review by keeping CooperSurgical and expanding its share repurchase programme by $1 billion.

Axogen is buying the maker of NerveTape, the first FDA-approved sutureless peripheral nerve repair device, in a deal expected to close in Q4 2026.

The former Bristol Myers Squibb CEO brings 35 years of biopharma experience to CD&R's healthcare investment and portfolio strategy.

The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9

Tarsus gains worldwide rights to Phase 3 oral candidate ALK-001 for Stargardt disease, a blinding inherited retinal condition with no approved therapy.

Ascendis Pharma will pay BioMarin royalties of up to 20% on navepegritide net sales through May 2030 to resolve all litigation between the two companies.

The NYSE-listed musculoskeletal device maker is buying Durham-based Higgs Boson Health to build out a surgical intelligence and patient-journey platform.

Teva has entered a stalking-horse bid for BXCL501, a sublingual agitation treatment under FDA review with a PDUFA date of 14 November 2026.

BioXcel Therapeutics has entered Chapter 11 bankruptcy, naming Teva as stalking-horse bidder for IGALMI and a pending agitation sNDA.